八子补肾胶囊治疗早衰的随机双盲多中心安慰剂对照临床试验
本研究为随机双盲多中心安慰剂对照试验,纳入530例30-78岁受试者,评估八子补肾胶囊(BZBS)治疗早衰的症状、生活质量、端粒酶活性及端粒长度。结果显示BZBS可改善肾虚衰老评估量表(CFCKD-AES)和衰弱指标(TFI)评分,提高生活质量,改善老年亚组运动功能,并提升端粒酶含量,但与端粒长度增加无显著关联。
要点
- BZBS可改善早衰症状、衰弱评分及生活质量
- BZBS提升端粒酶活性,但不显著增加端粒长度
- 老年亚组运动功能(握力、平衡、步行速度等)改善
核心结论
- 八子补肾胶囊可改善早衰症状、衰弱评分和生活质量,并提升端粒酶活性,但与端粒长度增加无显著关联。
研究设计与样本
- 平行、多中心、双盲、随机、安慰剂对照试验,纳入530例30-78岁受试者,随机接受BZBS或安慰剂胶囊治疗12周。
主要发现
- 治疗12周后,BZBS组CFCKD-AES评分降低13.79,TFI评分降低1.50;安慰剂组分别降低6.42和0.58。
- BZBS组SF-36评分提高98.38,安慰剂组提高23.79。
- 老年亚组中,BZBS组五次坐立试验时间(FTSST)、握力、平衡试验、步行速度和肌肉量均改善。
- BZBS组端粒酶含量较安慰剂组增加150.04 ng/ml。
- 安慰剂组1例因发热退出,1例因妊娠退出;无严重不良事件导致停药,3例不良事件(1.14%)被主要研究者评估为与BZBS相关。
关键数值与推荐
- 主要结局为肾虚衰老评估量表(CFCKD-AES)和Tilburg衰弱指标(TFI)的变化。
- 次要结局包括SF-36、血清性激素水平、五次坐立试验时间(FTSST)、6分钟步行试验(6MWT)、握力、平衡试验、步行速度、肌肉量、端粒酶和端粒长度。
临床怎么用
- 对于30-78岁早衰人群,可考虑使用八子补肾胶囊改善肾虚衰老症状、衰弱状态和生活质量。
- 在老年亚组中,八子补肾胶囊可能有助于改善运动功能(握力、平衡、步行速度等)和肌肉量。
- 使用八子补肾胶囊可能提升端粒酶活性,但不应期望其显著延长端粒长度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: It is unclear whether traditional Chinese patent medicines can resist premature aging. This prospective study investigated the effects of Bazi Bushen Capsule (BZBS) which is a traditional Chinese patent medicine for tonifying the kidney essence on premature senility symptoms and quality of life, telomerase activity and telomere length. STUDY DESIGN AND METHODS: It was a parallel, multicenter, double-blind, randomized, and placebo-controlled trial. Subjects (n = 530) aged 30-78 years were randomized to receive BZBS or placebo capsules 12 weeks. The primary outcome was the clinical feature of change in kidney deficiency for aging evaluation scale (CFCKD-AES) and tilburg frailty indicator (TFI). The secondary outcomes were SF-36, serum sex hormone level, five times sit-to-stand time (FTSST), 6MWT, motor function test-grip strength, balance test, walking speed, muscle mass measurement, telomerase and telomere length. RESULTS: After 12 weeks of treatment, the CFCKD-AES and TFI scores in the BZBS group decreased by 13.79 and 1.50 respectively (6.42 and 0.58 in the placebo group, respectively); The SF-36 in the BZBS group increased by 98.38 (23.79 in the placebo group). The FTSST, motor function test grip strength, balance test, walking speed, and muscle mass in the elderly subgroup were all improved in the BZBS group. The telomerase content in the BZBS group increased by 150.04 ng/ml compared to the placebo group. The fever led one patient in the placebo group to discontinue the trial. One patient in the placebo group withdrew from the trial due to pregnancy. None of the serious AEs led to treatment discontinuation, and 3 AEs (1.14%) were assessed as related to BZBS by the primary investigator. CONCLUSIONS: BZBS can improve premature aging symptoms, frailty scores, and quality of life, as well as improve FTSST, motor function: grip strength, balance test, walking speed, and muscle mass in elderly subgroups of patients, and enhance telomerase activity, but it is not significantly associated with increasing telomere length which is important for healthy aging. TRIAL REGISTRY: https://www.chictr.org.cn/showproj.html?proj=166181.
引用
- Mei J, Ju C, Wang B, et al. The efficacy and safety of Bazi Bushen Capsule in treating premature aging: A randomized, double blind, multicenter, placebo-controlled clinical trial. Phytomedicine. 2024. PMID: 38838635. doi:10.1016/j.phymed.2024.155742
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。